Theme
Diagnostics '26: Precision Oncology & Tumor Profiling☆
12 tickers$130.26B market cap
Group: Diagnostics
CAI-9.80%15.0%
GH+203.57%14.0%
TEM-10.53%13.0%
NEO+131.15%10.0%
NTRA+104.38%10.0%
EXAS+95.76%8.0%
VCYT+17.51%7.0%
ADPT+106.54%6.0%
CSTL+43.41%6.0%
BNR+75.09%5.0%
MDXH—4.0%
PSNL+176.46%2.0%
As of Sep 18, 2026, 9:54 PM ET
Diagnostics '26: Precision Oncology & Tumor Profiling Constituents
Caris Life Sciences, Inc.CAI | 15.0% | -3.04% | 21.49% | 43.80% | 21.69% | 11.77% | 49.73% | 7.70% | -9.80% | 7.07% | 7.07% | $8.47B |
Guardant Health, Inc.GH | 14.0% | -2.03% | 10.88% | 11.48% | 8.57% | 74.76% | 90.10% | 310.44% | 203.57% | 606.50% | 35.84% | $24.07B |
Tempus AI, Inc.TEM | 13.0% | -3.14% | 21.18% | 57.83% | 25.11% | 31.93% | 46.30% | 56.15% | -10.53% | 55.40% | 93.39% | $13.64B |
Natera, Inc.NTRA | 10.0% | 0.84% | 13.41% | 17.94% | 14.60% | 60.46% | 76.70% | 156.70% | 104.38% | 190.56% | 192.33% | $52.90B |
NeoGenomics, Inc.NEO | 10.0% | 0.10% | 13.47% | 25.31% | 14.18% | 69.43% | 102.70% | 111.52% | 131.15% | 20.81% | -58.80% | $511.6M |
Exact Sciences CorporationEXAS | 8.0% | 0.00% | 0.00% | 0.00% | 0.00% | 3.30% | 1.48% | 135.44% | 95.76% | 48.12% | -3.00% | $20.03B |
Veracyte, Inc.VCYT | 7.0% | -1.91% | -8.01% | -4.01% | -10.09% | -7.24% | 6.72% | 29.61% | 17.51% | 12.89% | -22.28% | $3.18B |
Adaptive Biotechnologies CorporationADPT | 6.0% | 0.21% | 16.84% | 15.80% | 16.84% | 75.12% | 77.53% | 258.19% | 106.54% | 498.54% | -28.03% | $4.58B |
Castle Biosciences, Inc.CSTL | 6.0% | -3.92% | 2.70% | 15.90% | 0.61% | -13.51% | 13.78% | 66.64% | 43.41% | 15.76% | -54.29% | $1.08B |
Burning Rock Biotech LimitedBNR | 5.0% | 8.80% | 37.49% | 58.16% | 59.71% | -26.92% | -42.99% | 244.85% | 75.09% | 309.40% | -93.03% | $15.0M |
MDxHealth S.A.MDXH | 4.0% | — | — | — | — | — | — | — | — | -76.05% | -94.75% | $32.4M |
Personalis, Inc.PSNL | 2.0% | 1.05% | -3.07% | 15.67% | -5.69% | 102.14% | 77.59% | 351.97% | 176.46% | 176.56% | -26.72% | $1.75B |
| Average | 8.3% | -0.28% | 11.49% | 23.44% | 13.23% | 34.66% | 45.42% | 157.20% | 84.87% | 155.46% | -4.35% | $10.85B |
| Median | 7.5% | 0.00% | 13.41% | 15.90% | 14.18% | 31.93% | 49.73% | 135.44% | 95.76% | 51.76% | -24.50% | $3.88B |
| Std Dev | 3.9% | 3.31% | 12.46% | 20.13% | 18.21% | 41.62% | 43.26% | 112.37% | 67.42% | 204.46% | 77.92% | $14.88B |
| Min | 2.0% | -3.92% | -8.01% | -4.01% | -10.09% | -26.92% | -42.99% | 7.70% | -10.53% | -76.05% | -94.75% | $15.0M |
| Max | 15.0% | 8.80% | 37.49% | 58.16% | 59.71% | 102.14% | 102.70% | 351.97% | 203.57% | 606.50% | 192.33% | $52.90B |
| % Positive Tickers | 45.45% | 72.73% | 81.82% | 72.73% | 72.73% | 90.91% | 100.00% | 81.82% | 91.67% | 33.33% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
Diagnostics '26: Precision Oncology & Tumor Profiling tracks 12 publicly listed stocks in this theme: CAI, GH, TEM, NEO, NTRA, EXAS, VCYT, ADPT, CSTL, BNR, MDXH, PSNL. See the constituent table for details.